CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.22525733

Available online at: http://www.iajps.com Review Article

PHARMACOLOGICAL MANAGEMENT OF SPACE MOTION SICKNESS IN ASTRONAUTS: CURRENT EVIDENCE AND FUTURE PERSPECTIVES

Subahana Shaji [1], Amrutha Rajesh [2], Neeraja Sunil [3], Sofy Binu [4]

[1]Pharm D Intern,Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India
[2]Pharm D Intern,Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India
[3]Pharm D Intern,Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India
[4]Assistant Professor, Department of Pharmacy PracticeNazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India

Abstract:

Space motion sickness (SMS) is a common disorder that develops in astronauts during the early phase of spaceflight, mainly due to sensory conflict following exposure to microgravity. Symptomatic nausea, vomiting, dizziness and disorientation can affect both astronaut comfort and operational performance. Pharmacologic therapy remains an important strategy in managing these symptoms and drugs such as scopolamine, promethazine and meclizine are commonly used. These drugs work mainly by anticholinergic and antihistaminic mechanisms to reduce vestibular signaling and to prevent nausea and vomiting. However, adverse effects, especially sedation, drowsiness and impairment of cognitive and psychomotor performance, may represent important limitations to their effectiveness in the demanding environment of spaceflight. This narrative review discusses the pathophysiology of space motion sickness, the neuropharmacology of its development and pharmacological management. It also examines the pros and cons of commonly used drugs, stressing the need to balance symptom control with the need to keep astronauts alert and effective.

Keywords *- Space Motion Sickness, Astronauts, Microgravity, Scopolamine, Promethazine, Meclizine, Antiemetics, Pharmacological Countermeasures*

Corresponding author:

Subahana Shaji,
Pharm D Intern,
Nazareth College of Pharmacy,
Othera, Thiruvalla, Kerala, India

QR CODE

Please cite this article in press ***Subahana Shaji*** *et al.,* ***Pharmacological Management Of Space Motion Sickness In Astronauts: Current Evidence And Future Perspectives****. Indo Am. J. P. Sci, 2026; 13(09).*

INTRODUCTION:

Space motion sickness (SMS) is a common physiologic adaptation in astronauts particularly in the early stages of spaceflight when the body experiences microgravity. Symptoms can include nausea, vomiting, dizziness, headache, fatigue, and disorientation. These symptoms are generally transient and resolve as the body acclimates to the space environment, but they can have a profound impact on an astronaut's comfort, concentration and ability to perform mission-related tasks.

The development of SMS is mainly associated with changes in the normal interaction between the vestibular, visual and proprioceptive systems. In microgravity, the vestibular system receives different sensory information than under Earth's gravity, which causes a mismatch in the central nervous system. This abnormal sensory processing can activate neural pathways related to motion sickness and lead to gastrointestinal and autonomic reactions.

Pharmacological management of SMS is an important approach to control the condition and allow astronauts to continue with their activities with minimal interruption. Several medications including scopolamine, promethazine, meclizine and other antiemetics have been used or studied for this purpose. The drugs act primarily on neurotransmitter systems involved in vestibular signaling and nausea, particularly cholinergic and histaminergic systems. But good symptom control has to be weighed against side effects like drowsiness, sedation, blurred vision and impaired cognitive or psychomotor performance.

This balance is particularly critical in spaceflight, which presents unique challenges for astronauts who may need to stay alert and perform complex tasks while experiencing motion sickness. Therefore, it is important to know the pharmacological mechanisms, therapeutic effectiveness, routes of administration and adverse effects of available treatments for the choice of adequate countermeasures. This narrative review will discuss the pharmacological management of space motion sickness, emphasizing commonly used medications and the challenges of their use in the spaceflight environment.

LITERATURE SEARCH STRATEGY

Literature search for pharmacological treatment for space motion sickness was done using the database of PubMed. Terms like "space motion sickness," "astronauts," "microgravity," "scopolamine," "promethazine," "meclizine," "antiemetics," and "pharmacological countermeasures" and combination of some terms were considered as keywords. Original articles related to pharmacological treatment and reviews about the same were selected based on their relevancy to the mechanisms, effectiveness, modes of action, and side effects of pharmacological treatments.

PHARMACOLOGICAL MANAGEMENT OF SPACE MOTION SICKNESS IN ASTRONAUTS

Sensory conflict due to altered vestibular stimulation while exposed to microgravity is the main cause of space motion sickness. Altered processing in the central nervous system due to changes in the normal interaction of vestibular, visual and proprioceptive inputs may result in nausea, vomiting, dizziness and disorientation. The aim of pharmacological treatment is to reduce these symptoms by changing the neurotransmitter pathways involved in vestibular signaling and emesis. Common agents include the anticholinergic drug scopolamine and antihistamines such as promethazine and meclizine. Although these drugs can be effective for symptom relief, their use in astronauts is complicated by adverse effects, particularly sedation, drowsiness, and impaired cognitive and psychomotor performance. Thus, pharmacologic management of space motion sickness must balance effective symptom control and preservation of alertness and functional performance of astronauts. The following discussion addresses the mechanisms of space motion sickness, the pharmacology of commonly used medications, their therapeutic benefits and adverse effects, and the advantages and limitations of using them in the spaceflight environment.

1. Space Motion Sickness: Definition and Clinical Features

Space motion sickness (SMS) is a common complaint among astronauts, occurring especially in the early part of spaceflight. It develops as the body adjusts to the microgravity environment and can cause nausea, vomiting, dizziness, headache, sweating, fatigue and disorientation. Symptoms vary in severity and duration among individuals. While SMS generally decreases as one acclimates to microgravity, debilitating symptoms may interfere with routine activities and potentially impact an astronaut's ability to undertake critical mission-related functions.

2. Microgravity and the Development of Space Motion Sickness

Microgravity causes profound changes in the sensory information the body uses to maintain its balance and spatial orientation. On Earth, the vestibular system has a constant reference: gravity. Spaceflight induces a change in the signals received by the vestibular organs as a consequence of the loss of normal gravitational stimulation. These altered signals do not usually match up with the visual and proprioceptive information and produce a sensory mismatch. The central nervous system has to adapt to this new sensory environment and this adaptation period is thought to be an important factor in the development of SMS.

3. Role of the Vestibular System and Central Nervous System

The vestibular system is important in the development of motion sickness. The semicircular canals sense rotational movement . The otolith organs sense linear acceleration and gravity . Normally, these signals would be related to other sensory inputs. In microgravity, this relationship is broken. The CNS gets conflicting information from the vestibular, visual and proprioceptive systems and attempts to reorganize these signals. This sensory mismatch might activate neural pathways in the brainstem involved in nausea, vomiting, and autonomic responses, thereby producing the classic symptoms of SMS.

4. Neuropharmacology of Space Motion Sickness

Pharmacological mechanisms involved in motion sickness are closely related to the neurotransmitter systems of the vestibular pathways and central nervous system. The development of the symptoms of motion sickness appears to depend upon histaminergic and cholinergic neurotransmission. Vestibular signals involved in nausea and emesis are transmitted via histamine acting on H1 receptors and acetylcholine acting on muscarinic receptors. Hence, drugs that block these receptors can reduce the vestibular signaling and suppress the symptoms. This explains the use of antihistamines and anticholinergic drugs in the treatment of SMS from the pharmacological point of view.

5. Scopolamine

Scopolamine is an anticholinergic drug that is used to prevent and treat motion sickness. It works mainly by blocking muscarinic acetylcholine receptors in the vestibular pathways and the central nervous system. This reduces the transmission of abnormal vestibular signals that cause motion-sickness symptoms. Scopolamine has been used as a pharmacological countermeasure in astronauts and has been studied in combination with dextroamphetamine. But it may be limited by adverse effects such as drowsiness, dry mouth, blurring of vision and reduced alertness. These effects are particularly relevant during spaceflight, as astronauts need to maintain sufficient cognitive and psychomotor performance .

6. Promethazine

Promethazine is an antihistaminic antiemetic that has been widely used for the management of space motion sickness. The blockade of central H1 histamine receptors is its principal therapeutic effect, resulting in decreased vestibular stimulation and inhibition of nausea and vomiting. Promethazine has been useful for symptomatic relief in astronauts, especially when given after the onset of symptoms. Route of administration can be considered depending upon the severity of symptoms and the astronaut's ability to tolerate oral medication. However, promethazine has the potential to produce significant sedation and drowsiness that may affect alertness, concentration, mood and psychomotor performance.

7. Meclizine

Meclizine is a first-generation H1 antihistamine used to prevent and manage motion sickness. Its main effect is to decrease the histaminergic activity in the central vestibular pathways. This can help alleviate symptoms like nausea and dizziness. Meclizine is a useful pharmacological agent for motion sickness; however, its effects on the central nervous system, particularly drowsiness and decreased alertness, are significant limitations in astronauts. Thus, the potential for performance degradation must be considered when selecting this medication for use during spaceflight.

8. Other Pharmacological Approaches

Other medications and strategies have been examined for the management of motion sickness. These include antihistamines, anticholinergic agents and antiemetic drugs that act on different neurotransmitter pathways. Combination therapy has also been examined as a way to improve symptom control and possibly lower the drawbacks of medications. The choice of treatment may depend on the severity of motion sickness symptoms the timing of administration the route of administration the response of each person and the type of activity the astronaut must carry out.

9. Adverse Effects and Astronaut Performance

One of the biggest drawbacks associated with pharmacological management of SMS is the adverse effects that may impair the performance of astronauts. Sedation/drowsiness is especially important, since most of the widely used medications affect the CNS. Other possible adverse effects include blurred vision, dry mouth, poor concentration, decreased coordination, and slow psychomotor responses. Even though these adverse effects may be tolerable during routine treatment on the ground, they become serious issues in space flight when astronauts need to conduct complicated operations, use machinery, make quick decisions and handle emergencies. Thus, treatment needs to be aimed at preventing both nausea/vomiting and preserving cognitive/psychomotor functions.

10.Advantages and Limitations of Pharmacological Treatment

Pharmacotherapy represents a feasible means of alleviating symptoms of SMS and enabling astronauts to perform their tasks in spite of nausea and vomiting. The use of different drugs and methods of drug delivery enables the physician to choose the most appropriate therapy for each case individually. Nevertheless, pharmacotherapy does not solve the problem and may show variable efficacy along with some adverse central nervous system effects. The ratio between alleviation of symptoms and impairment caused by medications is an important issue. A drug which shows effective treatment of SMS but induces significant sedation may not be used in those cases when high performance of astronauts is essential.

11. Future Perspectives

Future pharmacotherapy of SMS should aim at the effective treatment of symptoms without causing any sedation and impairing cognitive and psychomotor functions of an astronaut. The knowledge of individual susceptibility to the syndrome along with the correct dosing and route of drug delivery as well as adequate combination therapy may help to achieve better results.

DISCUSSION

Space motion sickness is a significant physiological challenge during human spaceflight, particularly during the initial adaptation to microgravity. Its development is closely related to altered vestibular stimulation and sensory conflict between vestibular, visual, and proprioceptive inputs. This makes the vestibular system and its associated neurotransmitter pathways attractive targets for pharmacological intervention. For these reasons, the principal pharmacologic modalities of treatment of SMS have included anticholinergic and antihistaminic agents.

Scopolamine, promethazine and meclizine are available medications that can be helpful in relieving nausea, vomiting and other symptoms of motion sickness. However, their effects are not restricted to the pathways for motion sickness. These drugs may cause drowsiness, sedation, impaired concentration, blurred vision and decreased psychomotor performance, because of their actions on the neurotransmitter systems of the central nervous system. This is a significant clinical and operational problem for astronauts who often have to carry out complex tasks requiring sustained attention, coordination and quick decision-making.

Promethazine has shown particular usefulness when administered after the onset of symptoms, while scopolamine and meclizine provide alternative approaches based on their anticholinergic and antihistaminic actions, respectively. The choice of medication may depend on symptom severity, route of administration, individual response, and the operational demands placed on the astronaut. Although combination approaches may improve symptom control, they can also increase the risk of adverse effects. Therefore, pharmacological management should not be based solely on the ability of a drug to suppress nausea and vomiting but should also consider its effect on overall astronaut performance.

Another problem is that people can vary widely in their response to motion-sickness drugs. Factors that may influence treatment effectiveness include susceptibility to SMS, dose, timing of administration, route of delivery, and adaptation to microgravity. Thus, there is a need for treatment strategies that provide reliable symptom control with minimal impairment. This is especially true for future long-duration missions, where maintaining astronaut performance over the duration of the mission will be critical.

CONCLUSION:

Space motion sickness is one of the frequent results of adjustment to microgravity and is mainly caused by changes in vestibular signals and sensory conflict in the central nervous system. The use of pharmacological agents like scopolamine, promethazine, and meclizine proves their efficiency and makes them useful for treatment of astronauts. Yet, sedation, drowsiness, and problems with cognition and psychomotorics are still considerable drawbacks of these medications. It means that the best possible pharmacological treatment should provide for the combination of an efficient management of motion-sickness symptoms and an adequate state of alertness and performance of astronauts.

REFERENCES:

1. Khalid A, Prusty PP, Arshad I, Gustafson HE, Jalaly I, Nockels K, Bentley BL, Goel R, Ferre ER. Pharmacological and non-pharmacological countermeasures to Space Motion Sickness: a systematic review. Frontiers in neural circuits. 2023 Jun 16;17:1150233.
2. Buckey JC, Lan M, Lewis LD. Space travel-associated motion sickness and its treatment. British Journal of Clinical Pharmacology. 2026 Jan;92(1):5-10.
3. Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviation, space, and environmental medicine. 1993 Mar 1;64(3):230-3.
4. Davis JR, Jennings RT, Beck BG. Comparison of treatment strategies for space motion sickness. Acta Astronautica. 1993 Aug 1;29(8):587-91.

5. Cowings PS, Toscano WB, Deroshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviation, space, and environmental medicine. 2000 Oct 1;71(10):1013-22.
6. McLaughlin MF, Donoviel DB, Jones JA. Novel indications for commonly used medications as radiation protectants in spaceflight. Aerospace medicine and human performance. 2017 Jul 1;88(7):665-76.
7. Weerts AP, De Meyer G, Pauwels G, Vanspauwen R, Dornhoffer JL, Van de Heyning PH, Wuyts FL. Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man. Audiology and Neurotology. 2012 Jun 1;17(4):235-42.
8. Graybiel A, Lackner JR. Treatment of severe motion sickness with antimotion sickness drug injections. Aviation, space, and environmental medicine. 1987 Aug 1;58(8):773-6.
9. Graybiel A, Lackner JR. Treatment of severe motion sickness with antimotion sickness drug injections. Aviation, space, and environmental medicine. 1987 Aug 1;58(8):773-6.
10. Abbott R, Weinrich MM, Keller NW, Wright TJ, Dunbar BJ, Denise P, Kennedy DM, Diaz-Artiles A. Promethazine Effects on Motion Sickness During Altered Gravity Induced by Parabolic Flight. Aerospace Medicine and Human Performance. 2025 Nov 1;96(11):976-84.